Professor Annelies Wilder-Smith Named New Senior Advisor to Dengue Vaccine Initiative

WASHINGTON, DC – March 6, 2015 – The members of the Dengue Vaccine Initiative (DVI) consortium, the International Vaccine Institute, the Johns Hopkins University International Vaccine Access Center, the Sabin Vaccine Institute and the World Health Organization, are delighted to announce the appointment of Professor Annelies Wilder-Smith as Senior Advisor to the DVI, effective immediately.

Every three months, the Dengue Vaccine Initiative (DVI) highlights a “Dengue Champion,” calling attention to that person’s contribution to the dengue vaccine research field and their commitment to the fight against dengue fever. Dr.

by Dr. Giovanini Coelho 

Dr. Capeding led the first Phase 3 trial ever completed for a dengue vaccine candidate.

This blog was originally posed on the Dengue Vaccine Initiative website
 
This year’s Americas Dengue Prevention Board (DPB)

In a new editorial published in PLOS NTDs, “The NTDs and Vaccine Diplomacy in Latin America: Opportunities for United States Foreign Policy,” Sabin Vaccine Institute (Sabin) President Dr.

Titled, “New chapter unfolding in the fight against dengue with an unwritten ending,” the Dengue Vaccine Initiative’s (DVI) editorial just published in the October issue of Transactions

Pages